

February 13, 2020

TAKE/BSE/2019-20

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001

TAKE/NSE/2019-20

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Dear Sir/Madam,

Sub: Press Release and Earnings Release
Ref: NSE Scrip Code: TAKE & BSE Scrip Code: 532890

We are pleased to enclose a press release for your reference and record.

Kindly take note of the same.

Thanking you.

Yours sincerely,
For TAKE Solutions Limited



Avaneesh Singh
Company Secretary



Encl: As above.



TAKE Solutions announces Q3FY20 results

Revenue up by 25% Y-o-Y to INR 6,511 Mn

Chennai - India, February 13, 2020: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences, today announced its financial results for Q3FY20. The company posted quarterly revenue of INR 6,511 Mn, registering 7.0% growth compared to the previous quarter.

| Particulars | Q3 FY20 | Q3 FY19 | Change (%) |
|------------------|---------|---------|------------|
| | | | Y-o-Y |
| Op. Revenue | 6,511.1 | 5,216.4 | 24.8% |
| Op. EBITDA | 1,083.3 | 882.3 | 22.8% |
| Margin | 16.6% | 16.9% | |
| Net Profit (PAT) | 511.4 | 363.7 | 40.6% |
| Margin | 7.9% | 7.0% | |
| Diluted EPS | 3.45 | 2.44 | |

Key highlights from this quarter:

- Revenue at **INR 6,511 Mn**; growth of **24.8% Y-o-Y** and **7.0% Q-o-Q**; Profit at **INR 511 Mn**, growing at **40.6% Y-o-Y**
- Earnings before Interest, Depreciation and Tax (EBITDA) for Q3FY20 stood at **INR 1.083Mn**, higher by **22.8%** against **INR 882.3 Mn** in Q3FY19
- ISO 9001:2015 recertification for our Frankfurt and Berlin offices
- 7 customer audits with zero critical findings

Srinivasan H R, Vice Chairman and Managing Director, TAKE Solutions said, *“TAKE has recorded a strong revenue growth of 7% as compared to the last quarter. We are delighted that our post merger milestones of our recent acquisitions (DataCeutics and KAI Research) have successfully completed and the synergies have started to contribute towards increase in client base. The focus for coming quarters will continue to be on penetrating Global markets.”*

About TAKE Solutions

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Our range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Our global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers.



With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with YTD Q3 FY 20 revenues touching INR 18,422 Mn (USD 262 Mn).

For more details, please visit www.takesolutions.com

For media information:

Rajeswari Pradeep Kumar, TAKE Solutions, +91 44 66110700, rajeswari.p@takesolutions.com